# Trial of IMO-8400 in Adult Patients With Dermatomyositis

> **NCT02612857** · PHASE2 · COMPLETED · sponsor: **Idera Pharmaceuticals, Inc.** · enrollment: 30 (actual)

## Conditions studied

- Dermatomyositis

## Interventions

- **DRUG:** IMO-8400 Dose Group 1
- **DRUG:** IMO-8400 Dose Group 2
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02612857
- **Lead sponsor:** Idera Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-11
- **Primary completion:** 2018-05-16
- **Final completion:** 2018-06
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2019-10-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02612857

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02612857, "Trial of IMO-8400 in Adult Patients With Dermatomyositis". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02612857. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*